Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Jan 2022
Historique:
received: 31 08 2021
revised: 10 11 2021
accepted: 15 11 2021
pubmed: 21 11 2021
medline: 27 1 2022
entrez: 20 11 2021
Statut: ppublish

Résumé

High mannose has previously associated with insulin resistance and cardiovascular disease (CVD). Our objective is to establish whether mannose is associated with anatomical evidence of coronary artery disease (CAD). Plasma mannose concentrations were measured by liquid chromatography/tandem mass spectrometry in a discovery cohort (n = 513) and a validation cohort (n = 221) of carefully phenotyped individuals. In both cohorts CAD was quantitated using state-of-the-art imaging techniques (coronary computed coronary tomography angiography (CCTA), invasive coronary angiography and optical coherence tomography). Information on subsequent CVD events/death was collected. Associations of mannose with angiographic variables and biomarkers were tested using univariate and multivariate regression models. Survival analysis was performed using the Kaplan-Meier estimator. Mannose was related to indices of CAD and features of plaque vulnerability. In the discovery cohort, mannose was a marker of quantity and quality of CCTA-proven CAD and subjects with a mannose level in the top quartile had a significantly higher risk of CVD events/death (p = 3.6e-5). In the validation cohort, mannose was significantly associated with fibrous cap thickness < 65 μm (odds ratio = 1.32 per each 10 μmol/L mannose change [95% confidence interval, 1.05-1.65]) and was an independent predictor of death (hazard ratio for mannose≥vs < 84.6 μmol/L: 4.0(95%CI, 1.4-11.3), p = 0.006). The current data add novel evidence that high mannose is a signature of CAD with a vulnerable plaque phenotype, consistently across measures of severity of vessel involvement and independent of the traditional correlates of CVD, and that it is an independent predictor of incident adverse outcomes.

Sections du résumé

BACKGROUND BACKGROUND
High mannose has previously associated with insulin resistance and cardiovascular disease (CVD). Our objective is to establish whether mannose is associated with anatomical evidence of coronary artery disease (CAD).
METHODS METHODS
Plasma mannose concentrations were measured by liquid chromatography/tandem mass spectrometry in a discovery cohort (n = 513) and a validation cohort (n = 221) of carefully phenotyped individuals. In both cohorts CAD was quantitated using state-of-the-art imaging techniques (coronary computed coronary tomography angiography (CCTA), invasive coronary angiography and optical coherence tomography). Information on subsequent CVD events/death was collected. Associations of mannose with angiographic variables and biomarkers were tested using univariate and multivariate regression models. Survival analysis was performed using the Kaplan-Meier estimator.
RESULTS RESULTS
Mannose was related to indices of CAD and features of plaque vulnerability. In the discovery cohort, mannose was a marker of quantity and quality of CCTA-proven CAD and subjects with a mannose level in the top quartile had a significantly higher risk of CVD events/death (p = 3.6e-5). In the validation cohort, mannose was significantly associated with fibrous cap thickness < 65 μm (odds ratio = 1.32 per each 10 μmol/L mannose change [95% confidence interval, 1.05-1.65]) and was an independent predictor of death (hazard ratio for mannose≥vs < 84.6 μmol/L: 4.0(95%CI, 1.4-11.3), p = 0.006).
CONCLUSION CONCLUSIONS
The current data add novel evidence that high mannose is a signature of CAD with a vulnerable plaque phenotype, consistently across measures of severity of vessel involvement and independent of the traditional correlates of CVD, and that it is an independent predictor of incident adverse outcomes.

Identifiants

pubmed: 34800594
pii: S0167-5273(21)01855-6
doi: 10.1016/j.ijcard.2021.11.038
pii:
doi:

Substances chimiques

Biomarkers 0
Mannose PHA4727WTP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-92

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Ele Ferrannini (E)

CNR Institute of Clinical Physiology, Pisa, Italy. Electronic address: ferranni@ifc.cnr.it.

Nikolaus Marx (N)

University Hospital RWTH, Aachen, Germany.

Daniele Andreini (D)

Centro Cardiologico Monzino, IRCCS, Milan, Italy; Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Italy.

Beatrice Campi (B)

CNR Institute of Clinical Physiology, Pisa, Italy.

Alessandro Saba (A)

Laboratory of Biochemistry, Department of Surgical, Medical, Molecular & Critical Area Pathology, University of Pisa, Italy.

Marco Gorini (M)

ANMCO Research Center, Heart Care Foundation, Florence, Italy.

Giulia Ferrannini (G)

Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Andrea Milzi (A)

University Hospital RWTH, Aachen, Germany.

Marco Magnoni (M)

IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.

Attilio Maseri (A)

ANMCO Research Center, Heart Care Foundation, Florence, Italy.

Aldo P Maggioni (AP)

ANMCO Research Center, Heart Care Foundation, Florence, Italy.

Mathias Burgmaier (M)

University Hospital RWTH, Aachen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH